Nancy Reau, MD

Thoughts on the Current State of PBC Management

Video content above is prompted by the following:

Please share your concluding thoughts about management of PBC.

Videos

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by the progressive destruction of small and medium-sized bile ducts within the liver. This destruction is primarily mediated by autoreactive T lymphocytes targeting the epithelial cells of the bile ducts. The ensuing cholestasis leads to the accumulation of toxic bile acids, causing hepatocellular damage and inflammation. Over time, this chronic inflammatory process results in fibrosis and eventually cirrhosis. The pathophysiology of PBC is influenced by genetic predispositions and environmental factors, contributing to its complex etiology and progression.

The panel of experts offers expert insights and concluding thoughts on the management of primary biliary cholangitis (PBC), emphasizing the importance of personalized treatment strategies, monitoring, and the evolving role of new therapies in improving patient outcomes.

Outcomes and Adoption of PPAR Agonists in PBC

What could be some potential challenges with the adoption of PPAR agonists for PBC?

The panel of experts addresses potential challenges in the adoption of peroxisome proliferator-activated receptor  (PPAR) agonists for primary biliary cholangitis (PBC), including barriers to access, patient selection, and long-term treatment considerations.

Treatment Response to PPAR Agonists and Other Therapies in PBC

How do you determine if treatment is effective in PBC?

The panel of experts discuss how to determine the effectiveness of treatment in primary biliary cholangitis (PBC), focusing on key clinical markers, biochemical responses, and patient outcomes.

Integration of PPAR Agonists in Treatment Landscape of PBC

How do you envision the uptake and integration of PPAR agonists into the current treatment landscape for PBC? What would you recommend for someone who is taking a fibrate for PBC?

The panel of experts explore the potential integration of peroxisome proliferator-activated receptor (PPAR) agonists into the current treatment landscape for primary biliary cholangitis (PBC) and provides recommendations for patients currently taking fibrates for managing the disease.

Nancy Reau, MD

Articles